Health Canada has given approval for neffy, a nasal spray epinephrine for use in Canada. It will be

available in jpharmacies in Canada in the summer 2026. Thanks to Food Allergy Canada for sharing this

exciting information.

Food Allergy Canada is a nationally registered charity committed to educating, supporting, and advocating for the over 3 million Canadians impacted by food allergy. 

Today, ALK Canada announced that neffy® epinephrine nasal spray has been approved by Health Canada. The approval is for a 2 mg dose for treating anaphylaxis in adults and children weighing 30 kg (66 lbs) or greater. 
ALK has advised that neffy will be widely available in pharmacies across Canada starting in summer 2026.
With neffy, Canadians will have access to a different option for an epinephrine device.
Read ALK’s statement and visit neffy.ca for additional information. Plus, read these FAQs to address other questions you may have about neffy, including how to access it.
We have advocated on your behalf for greater access to epinephrine The approval of neffy marks an important step forward — giving Canadians another option and the ability to choose the device that best meets their needs.
Our advocacy has focused on ensuring there are at least two affordable epinephrine device options available in Canada, helping to reduce the risks associated with a single-source market, including supply shortages and limited flexibility.
We’ve worked closely with the Government of Canada, provincial governments, pharmaceutical companies, and other key stakeholders to help make this progress possible — always with the goal of improving access and choice for the community.
As new epinephrine device options continue to emerge, we remain committed to advocating strongly and consistently to ensure Canadians can access the full range of options.Sincerely,Jennifer Gerdts, Executive Director
Food Allergy Canada
 
Food Allergy Canada | 505 Consumers Road Suite 507 | Toronto, ON M2J 4V8 CAUnsubscribe | Update Profile | Constant Contact Data Notice